Topics

CASI's In-licensed CAR-T Candidate to Start China Trials for Leukemia/Lymphoma

02:46 EST 5 Dec 2019 | ChinaBio Today

CASI Pharma announced China approval to start clinical trials of CNCT19, a CD19 CAR-T treatment, in leukemia and lymphoma patients. Earlier this year, CASI acquired global rights to the candidate from Juventas Cell Therapy of Beijing in exchange for an $11.6 million investment in Juventas rather than an upfront payment. Juventas retains responsibility for trials of CNCT19. CASI, a Maryland-China biopharma, said the CD19 CAR-T therapy will be tested in patients with relapsed/refractory B-cell acute lymphoblastic leukemia and relapsed/refractory B-cell non-Hodgkin lymphoma. More details....

Stock Symbol: (NSDQ: CASI)

Share this with colleagues:

Original Article: CASI's In-licensed CAR-T Candidate to Start China Trials for Leukemia/Lymphoma

NEXT ARTICLE

More From BioPortfolio on "CASI's In-licensed CAR-T Candidate to Start China Trials for Leukemia/Lymphoma"

Quick Search

Relevant Topic

Clinical Approvals
Clinical trials are a set of procedures in medical research conducted to allow safety (or more specifically, information about adverse drug reactions and adverse effects of other treatments) and efficacy data to be collected for health interventions (e.g...